左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果分析
x

请在关注微信后,向客服人员索取文件

篇名: 左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果分析
TITLE:
摘要: 目的:评估左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果,为我省急性心力衰竭患者治疗方案的合理选用提供参考。方法:根据全球SURVIVE临床试验数据,结合目前我省医疗及消费水平,采用成本-效果分析法分别对左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果及结果敏感度进行分析。结果:对于急性心力衰竭患者,短期(5 d)给予左西孟旦治疗的人均总成本为10 490.00元,多巴酚丁胺为6 637.18元。成本-效果分析及敏感度试验结果均表明,我省人均国内生产总值(GDP)<左西孟旦相较于多巴酚丁胺的增量成本-效果比<我省3倍GDP。结论:在我省目前的经济水平下,对于急性心力衰竭患者,采用左西孟旦的治疗方案较传统药物具有成本-效果优势。
ABSTRACT: OBJECTIVE: To evaluate cost-effectiveness of levosimendan versus dobutamine for acute heart failure, in order to provide reference for rational selection of therapeutic regimen for acute heart failure patients. METHODS: According to SURVIVE clinical trial data, cost-effectiveness analysis was adopted to analyze cost-effectiveness and sensitivity of levosimendan versus dobutamine for acute heart failure, based on medical and consumption level. RESULTS: For acute heart failure patients, total cost per capita of shot-term levosimendan (5 d) was 10 490.00 yuan, and that of dobutamine was 6 637.18 yuan. Cost-effectiveness analysis and sensitivity test indicated that the incremental cost-effectiveness ratio of levosimendan to dobutamine was lower than three times over per capita GDP of Hubei province and was higher than per capita GDP.  CONCLUSIONS: Levosimendan appears to have cost-effectiveness advantage in the treatment of acute heart failure under the current economic situation of Hubei province in China.
期刊: 2016年第27卷第11期
作者: 吴玥,戎佩佩,沈秉正,冯静,李萌,周本宏
AUTHORS: WU Yue,RONG Peipei,SHEN Bingzheng,FENG Jing,LI Meng,ZHOU Benhong
关键字: 左西孟旦;多巴酚丁胺;急性心力衰竭;成本-效果分析
KEYWORDS: Levosimendan; Dobutamine; Acute heart failure; Cost-effectiveness analysis
阅读数: 149 次
本月下载数: 10 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!